Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib versus platinum-doublet adjuvant therapy after resection for stage II-IIIA EGFR/ALK-negative NSCLC
ChiCTR2000038348Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jan 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of anlotinib, cisplatin, carboplatin, pemetrexed and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Median disease-free survival. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
anlotinibcisplatincarboplatinpemetrexedpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000038348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038348.